Trials

The effect of low-dose radiotherapy on pain in early osteoarthritis of the hip

Clinically node negative breast cancer patients undergoing breast conserving therapy: sentinel lymph node procedure versus follow-up

Neo-adjuvant chemotherapy followed by surgery vs. neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery vs. neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer

Influence of the intestinal microbiome on the outcome of treatment with preoperative chemoradiotherapy in patients with resectable oesophageal carcinoma

Prospective data collection initiative on colorectal cancer

The (cost)effectiveness of neoadjuvant folfirinox versus neoadjuvant gemcitabine based chemoradiotherapy and adjuvant gemcitabine for (borderline) resectable pancreatic cancer

Rectal preserving treatment for early rectal cancer. A multi-centered randomised trial of radical surgery versus adjuvant radiotherapy after local excision for early rectal cancers

Transarterial Chemoembolization with Drug-Eluting Beads (standard arm) versus Stereotactic Body Radiation Therapy (experimental arm) for hepatocellular carcinoma

Evaluating the applicability of a mobile application in the communication with trial participants and investigating the feasibility and preferences of a mobile application for delivering patient registered outcome measures (PROMs) compared to paper questionnaires

External beam radiochemotherapy and MRI based adaptive BRAchytherapy in locally advanced CErvical cancer

Randomised Phase III Trial of molecular profile-based versus standard recommendations for adjuvant radiotherapy for women with early stage endometrial cancer

A nurse-led sexual rehabilitation programme for women with gynaecological cancers receiving radiotherapy: a randomized multicentre trial

Evaluation of the impact of a decision aid tool for patients with advanced larynx cancer and assessment of its influence on shared decision making.

A dedicated multidisciplinary head and neck cancer rehabilitation program compared to usual supportive care for patients treated with concomitant chemo-radiotherapy: assessment of effectiveness and cost-effectiveness in a multicenter prospective observational study

Uniform FDG-PET guided GRAdient Dose prEscription to reduce late Radiation Toxicity (UPGRADE-RT): a randomised controlled trial with dose reduction to the elective neck in head and neck squamous cell carcinoma

Assessing the Effect of Decision Support for Prophylactic Cranial Irradiation (PCI) for Small-Cell Lung Cancer Patients

Elderly with locally advanced Lung cancer: Deciding through geriatric Assessment  on the oPtimal Treatment strategy

Patients continue the same immune therapy they already received and get radiotherapy to one lesion. The lesion may or may not be symptomatic, but it should be a lesion that increased in size, i.e. containing resistant cells, according to RECIST 1.1 criteria. The preferred radiotherapy dose is 24 Gy in 3 fractions (dosage on the 10 Gy isodose is allowed), but other fractionation schedules (e.g. 30 Gy/ 10 fractions, 20 Gy/ 5 fractions, 20-24 Gy / 1 fraction for SRS) are allowed if these are standard for a certain location or palliative indication in the body.

A phase III trial of marizomib in combination with standard temozolomide-based radiochemotherapy versus standard temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma.

Primary intracranial germ-cell tumours in adults; evaluation and treatment protocol

A randomized, placebo controlled phase 2b/3 study of ABT-414 with concurrent chemoradiation and adjuvant Temozolomide in subjects with newly diagnosed glioblastoma (GBM) with Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance 1)

Medulloblastoma in Adults Treatment Protocol, Dutch Society for Neuro-Oncology (LWNO)

DOsis REductie van preoperatieve radiotherapie bij het MYxoidLiposarcoom

Focal ablative stereotactic radiosurgery for cancers of the kidney.

A randomized study between whole gland prostate brachytherapy (control arm) and hemigland prostate brachytherapy (experimental arm). The study population consists of patients with proven unilateral significant adenocarcinoma of the prostate.

Prostate cancer Immune profiling before, during and after HDR-brachytherapy in local relapsed prostate cancer.

The impact of the implementation of a decision aid tool for prostate cancer patients on the decision making process